Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 676 - 700 of 14534 in total

Methoxy polyethylene glycol-epoetin beta

Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Hepatitis B Vaccine (Recombinant)

Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … the chronic complications such as chronic active hepatitis and cirrhosis. ... epidemiology vary widely among geographical areas and population subgroups. ... Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Bacterial and viral vaccines, combined ... haemophilus influenzae B and hepatitis B …

Rilonacept

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Hemoglobin

The respiratory protein of the red blood cells. It consists primarily of globin and heme.
Approved
Experimental
Investigational
Matched Description: … It consists primarily of globin and heme. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Susoctocog alfa

Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for ... porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and …
Matched Categories: … Blood and Blood Forming Organs …

Aceclofenac

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the...
Approved
Investigational
Matched Description: … Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and ... analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ... displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and …
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Polatuzumab vedotin

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Lorazepam

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Migalastat

Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Sutilain

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000...
Approved
Withdrawn
Matched Description: … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. ... Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored …
Matched Categories: … Enzymes and Coenzymes …

Efalizumab

Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mirikizumab

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and ... [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ansuvimab

Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … to be superior, with improved patient survival and faster viral clearance rates. ... [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. ... evidenced by the previously approved INMAZEBâ„¢ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Fosdenopterin

Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites ... paraplegia, myoclonus, and opisthotonus. ... a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Estazolam

A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Matched Description: … A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas …

Nilutamide

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … the growth of normal and malignant prostatic tissue. ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Sotrovimab

Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Melphalan flufenamide

Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved ... which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Cefixime

Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Investigational
Matched Description: … , and meningitis. ... a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and ... [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation …
Matched Categories: … cefixime and ornidazole ... cefixime and azithromycin …

Tromethamine

An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed,...
Approved
Matched Description: … cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used ... It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …

Ascorbyl phosphate

Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ascorbyl phosphate and sodium ascorbyl phosphate. These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% . As vitamin C is susceptible to breakdown of compound...
Approved
Matched Description: … ascorbyl phosphate and sodium ascorbyl phosphate. ... Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ... phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin …
Matched Categories: … Vitamin C and analogues …

Ibrutinib

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Interferon alfa-n3

Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Approved
Investigational
Matched Description: … for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Obiltoxaximab

Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Approved
Matched Description: … infection and death caused by anthrax toxin. ... Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Displaying drugs 676 - 700 of 14534 in total